Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 41Myelodysplastic Syndromes 37Leukemia 36Leukemia, Lymphocytic, Chronic, B-Cell 27Lymphoma 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Multiple Myeloma 21Lymphoma, Non-Hodgkin 20Lymphoma, Follicular 20Lymphoma, Large B-Cell, Diffuse 17Lymphoma, Mantle-Cell 16Congenital Abnormalities 16Melanoma 15Lymphoma, B-Cell, Marginal Zone 14Hodgkin Disease 14Myeloproliferative Disorders 13Leukemia, Myelogenous, Chronic, BCR-ABL Positive 13Burkitt Lymphoma 13Neoplasms, Plasma Cell 12Primary Myelofibrosis 11Leukemia, Myeloid, Accelerated Phase 11Neoplasm Metastasis 10Lymphoma, Large-Cell, Immunoblastic 9Leukemia, Myelomonocytic, Chronic 9Blast Crisis 9Anemia, Refractory, with Excess of Blasts 9Waldenstrom Macroglobulinemia 8Leukemia, Prolymphocytic 8Hematologic Neoplasms 8Graft vs Host Disease 8

Interventions

umbralisib 1ublituximab 1marizomib 1fludarabine phosphate 1fludarabine 1enzastaurin 1durvalumab 1carotuximab 1brigatinib 1binimetinib 1axicabtagene ciloleucel 1Zoledronic Acid 1Vitamin D 1Receptors, Interleukin-6 1Oxaliplatin 1Leucovorin 1Irinotecan 1Interleukin 1 Receptor Antagonist Protein 1Gemcitabine 1Folfox protocol 1Fluorouracil 1Cyclophosphamide 1Cisplatin 1Calcium 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Disease Progression × fludarabine phosphate × Clear all
NCT04205838 2026-02-27

Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma

Jonsson Comprehensive Cancer Center

Phase 2 Terminated
23 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡